
Aerovate Therapeutics Investor Relations Material
Latest events

Q1 2025
25 Apr, 2025

Q4 2024
27 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Aerovate Therapeutics Inc
Access all reports
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases. The company's lead product candidate is AV-101, a dry powder inhaled formulation of imatinib, designed to treat pulmonary arterial hypertension (PAH). This formulation aims to deliver the drug directly to the lungs, targeting the underlying disease mechanisms while minimizing systemic side effects. Aerovate Therapeutics is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Nintendo: From Game Boy and Pokémon to Switch 2 and Mario Kart
Nintendo went from card maker to cultural icon, shaping modern entertainment through hardware innovation and world-famous characters.
19 Jun 2025
)
Ron Vachris: From Forklift Driver to CEO at Costco
Ron Vachris took over as Costco CEO in 2024, following a 40-year journey from warehouse floors to the top of one of retail's most admired companies.
18 Jun 2025
)
Luca de Meo: Succeeding Pinault as the New CEO of Kering
Luca de Meo's leap from auto to luxury marks a bold new chapter as he becomes the first non-Pinault CEO to lead the Kering empire.
16 Jun 2025
Ticker symbol
AVTE
Country
🇺🇸 United States